Anti-CD28 humanized antibodies
US10364287B2 · kind B2 · utility
3Cited by
3References
14Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Dec 21, 2016 |
| Grant date | Jul 30, 2019 |
| Priority date | — |
| Expiry date | May 19, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to humanized antibodies directed against the human lymphocyte receptor CD28. When used in a monovalent form these antibodies are antagonists, i.e. capable of blocking of the CD28/B7 interaction, without activating CD28.These antibodies can be used in particular as therapeutic agents for blocking T cell activation through the CD28 receptor.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.